Limits...
Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells.

Kerros C, Cavey T, Sola B, Jauzac P, Allouche S - J. Exp. Clin. Cancer Res. (2009)

Bottom Line: opioid and somatostatin receptors (SSTRs) that can assemble as heterodimer were individually reported to modulate malignant cell proliferation and to favour apoptosis.XTT assays and cell cycle studies provide no evidence for a significant effect upon opioid or somatostatin receptors stimulation.Furthermore, neither direct effect nor potentiation of the Fas-receptor pathway was detected on apoptosis after these treatments. these data suggest that SSTRs or opioid receptors expression is not a guaranty for an anti-tumoral action in U266 cell line.

View Article: PubMed Central - HTML - PubMed

Affiliation: Laboratoire de biologie moléculaire et cellulaire de la signalisation, UPRES-EA 3919, IFR 146 ICORE, Université de Caen, Caen, France. ckerros@yahoo.fr

ABSTRACT

Background: opioid and somatostatin receptors (SSTRs) that can assemble as heterodimer were individually reported to modulate malignant cell proliferation and to favour apoptosis.

Materials and methods: SSTRs and opioid receptors expression were examined by RT-PCR, western-blot and binding assays, cell proliferation was studied by XTT assay and propidium iodide (PI) staining and apoptosis by annexin V-PI labelling.

Results: almost all human malignant haematological cell lines studied here expressed the five SSTRs. Further experiments were conducted on the human U266 multiple myeloma cells, which express also micro-opioid receptors (MOP-R). XTT assays and cell cycle studies provide no evidence for a significant effect upon opioid or somatostatin receptors stimulation. Furthermore, neither direct effect nor potentiation of the Fas-receptor pathway was detected on apoptosis after these treatments.

Conclusion: these data suggest that SSTRs or opioid receptors expression is not a guaranty for an anti-tumoral action in U266 cell line.

Show MeSH

Related in: MedlinePlus

Effect of Sst, Oct and Morph on U266 cell line viability. Exponentially growing cells were seeded and incubated for 24, 48 or 72 h with (A) somatostatin (Sst), (B) octreotide (Oct), (C) Sst alone or combined with 10 μM morphine (Morph). The SSTR antagonist cyclosomatostatin (Css) was also included. U266 cell viability was determined using the XTT assay and data were normalized to absorbance values obtained in control cells. Data are mean ± S.E.M of 5 to 7 different experiments performed in triplicate.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2698864&req=5

Figure 2: Effect of Sst, Oct and Morph on U266 cell line viability. Exponentially growing cells were seeded and incubated for 24, 48 or 72 h with (A) somatostatin (Sst), (B) octreotide (Oct), (C) Sst alone or combined with 10 μM morphine (Morph). The SSTR antagonist cyclosomatostatin (Css) was also included. U266 cell viability was determined using the XTT assay and data were normalized to absorbance values obtained in control cells. Data are mean ± S.E.M of 5 to 7 different experiments performed in triplicate.

Mentions: Cell viability was then evaluated using XTT assays. All experiments were done in culture medium containing FCS. U266 cells were treated or not (control) in the presence of either Sst or Oct, a SSTR2, 3 and 5 selective agonist [6,34], ranging from 100 pM to 10 μM during 24, 48 or 72 h. As depicted on the Figure 2A, Sst, even at high concentrations, was devoid of any significant effect on cell viability at 24, 48 or 72 h pretreatment. When cells were exposed to a selective SSTR antagonist, cyclosomatostatin (Css), alone or in combination with Sst, no significant effect was detected. Stimulation of SSTR2, 3 and 5 by Oct (100 pM to 10 μM) alone or in combination with 10 μM of Css for 24, 48 or 72 h was unable to promote any significant modification of cell viability (Figure 2B).


Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells.

Kerros C, Cavey T, Sola B, Jauzac P, Allouche S - J. Exp. Clin. Cancer Res. (2009)

Effect of Sst, Oct and Morph on U266 cell line viability. Exponentially growing cells were seeded and incubated for 24, 48 or 72 h with (A) somatostatin (Sst), (B) octreotide (Oct), (C) Sst alone or combined with 10 μM morphine (Morph). The SSTR antagonist cyclosomatostatin (Css) was also included. U266 cell viability was determined using the XTT assay and data were normalized to absorbance values obtained in control cells. Data are mean ± S.E.M of 5 to 7 different experiments performed in triplicate.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2698864&req=5

Figure 2: Effect of Sst, Oct and Morph on U266 cell line viability. Exponentially growing cells were seeded and incubated for 24, 48 or 72 h with (A) somatostatin (Sst), (B) octreotide (Oct), (C) Sst alone or combined with 10 μM morphine (Morph). The SSTR antagonist cyclosomatostatin (Css) was also included. U266 cell viability was determined using the XTT assay and data were normalized to absorbance values obtained in control cells. Data are mean ± S.E.M of 5 to 7 different experiments performed in triplicate.
Mentions: Cell viability was then evaluated using XTT assays. All experiments were done in culture medium containing FCS. U266 cells were treated or not (control) in the presence of either Sst or Oct, a SSTR2, 3 and 5 selective agonist [6,34], ranging from 100 pM to 10 μM during 24, 48 or 72 h. As depicted on the Figure 2A, Sst, even at high concentrations, was devoid of any significant effect on cell viability at 24, 48 or 72 h pretreatment. When cells were exposed to a selective SSTR antagonist, cyclosomatostatin (Css), alone or in combination with Sst, no significant effect was detected. Stimulation of SSTR2, 3 and 5 by Oct (100 pM to 10 μM) alone or in combination with 10 μM of Css for 24, 48 or 72 h was unable to promote any significant modification of cell viability (Figure 2B).

Bottom Line: opioid and somatostatin receptors (SSTRs) that can assemble as heterodimer were individually reported to modulate malignant cell proliferation and to favour apoptosis.XTT assays and cell cycle studies provide no evidence for a significant effect upon opioid or somatostatin receptors stimulation.Furthermore, neither direct effect nor potentiation of the Fas-receptor pathway was detected on apoptosis after these treatments. these data suggest that SSTRs or opioid receptors expression is not a guaranty for an anti-tumoral action in U266 cell line.

View Article: PubMed Central - HTML - PubMed

Affiliation: Laboratoire de biologie moléculaire et cellulaire de la signalisation, UPRES-EA 3919, IFR 146 ICORE, Université de Caen, Caen, France. ckerros@yahoo.fr

ABSTRACT

Background: opioid and somatostatin receptors (SSTRs) that can assemble as heterodimer were individually reported to modulate malignant cell proliferation and to favour apoptosis.

Materials and methods: SSTRs and opioid receptors expression were examined by RT-PCR, western-blot and binding assays, cell proliferation was studied by XTT assay and propidium iodide (PI) staining and apoptosis by annexin V-PI labelling.

Results: almost all human malignant haematological cell lines studied here expressed the five SSTRs. Further experiments were conducted on the human U266 multiple myeloma cells, which express also micro-opioid receptors (MOP-R). XTT assays and cell cycle studies provide no evidence for a significant effect upon opioid or somatostatin receptors stimulation. Furthermore, neither direct effect nor potentiation of the Fas-receptor pathway was detected on apoptosis after these treatments.

Conclusion: these data suggest that SSTRs or opioid receptors expression is not a guaranty for an anti-tumoral action in U266 cell line.

Show MeSH
Related in: MedlinePlus